Detalhe da pesquisa
1.
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.
Am Heart J
; 180: 22-8, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27659879